Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy, Safety and Immunogenicity of LAIV in Children and Adolescents
NCT02964065Phase 3Completed
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- Nov 2016
- Primary completion
- Aug 2017
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in influenza (2 arms), sponsored by Changchun BCHT Biotechnology Co. Primary endpoint: Percentage of Subjects With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Vaccine-like Strains). Started Nov 2016; status: completed.
02
Conditions
influenza
Beyond the preview
Go deeper on NCT02964065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964065.